Who Optimizes SG&A Costs Better? United Therapeutics Corporation or ADMA Biologics, Inc.

Biotech Giants: A Decade of SG&A Cost Strategies

__timestampADMA Biologics, Inc.United Therapeutics Corporation
Wednesday, January 1, 20144823869381287000
Thursday, January 1, 20156745968452612000
Friday, January 1, 20168494742316800000
Sunday, January 1, 201718092835330100000
Monday, January 1, 201822502922265800000
Tuesday, January 1, 201925910757336200000
Wednesday, January 1, 202035050817423900000
Friday, January 1, 202142896889467000000
Saturday, January 1, 202252458024487000000
Sunday, January 1, 202359020000477100000
Loading chart...

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, United Therapeutics Corporation and ADMA Biologics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, United Therapeutics consistently maintained higher SG&A expenses, peaking at approximately $487 million in 2022. In contrast, ADMA Biologics, with a more modest budget, saw its SG&A expenses grow from around $4.8 million in 2014 to nearly $59 million in 2023.

Despite the disparity in absolute numbers, both companies have shown a commitment to strategic spending. United Therapeutics' expenses grew by about 25% over the period, while ADMA Biologics experienced a staggering increase of over 1,100%. This data highlights the diverse strategies employed by biotech firms in managing operational costs, reflecting their unique market positions and growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025